 Eli Lilly has gone big in the name of neuroscience, paying $6.3 billion in a front-loaded deal for Centessa Pharmaceuticals and its sleep disorder pipeline. In recent years, U.K.-based Centessa has been focused on a portfolio of orexin receptor 2 (OX2R) agonists, which the biotech has been targeting at conditions related to the sleep-wake cycle. Centessa’s lead program is cleminorexton, formerly known as ORX750, which is undergoing a phase 2 study for two types of narcolepsy as well as idiopathic hypersomnia (IH). 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
